SynTra

Challenge

Viral vector production is complex, costly, slow (>4 months), and difficult to personalize, limiting scalability of cell and gene therapies. Personalized cell and gene therapies require a rapid, modular, and cost-efficient vector manufacturing process.

Solution

SynTra is a non-viral gene transfer platform, combining the Sleeping Beauty technology with synthetic DNA production for efficient, scalable, personalized cell and gene therapies. SynTra enables custom, clinical-grade vector production in less than a month, enabling truly individualized therapies.

Non-viral, synthetic, modular gene delivery

The Max Delbrück Center‘s proprietary Sleeping Beauty Transposase enables non-viral gene transfer with similar efficacies as viral vectors, but greatly reduced complexity (only DNA and RNA needed)
Fully synthetic, cell-free DNA production process, allowing a flexible and patient-specific vector generation for individualized therapies
Modular and fast pipeline, reducing custom vector production time from >4 months to <1 month
Combination of Sleeping Beauty Transposase-mediated gene transfer and synthetic DNA-Transposons reduces the patient-specific cell production to less than 2 months

Development status

TRL 4
DNA production pipeline allows small scale production of synthetic DNA transposons in less than a week
Proof of principle demonstrated, synthetic vectors showing comparable efficacy to current gold-standard vectors
Platform established and advancing toward automated, scalable manufacturing workflows